Aurobindo Pharma Ltd (IN:AUROPHARMA)
:AUROPHARMA
Top Page
Aurobindo Pharma Ltd
(AUROPHARMA)
Select Model
Select Model
Rating:74Outperform
Price Target:
₹1,511.00
▲(25.15% Upside)
Action:ReiteratedDate:11/15/25
Aurobindo Pharma's strong financial performance and bullish technical indicators are the primary drivers of its stock score. However, the high P/E ratio suggests potential overvaluation, and overbought technical conditions indicate caution for short-term investors. The absence of earnings call data and corporate events limits additional insights.
Positive Factors
Revenue & Margins
Sustained top-line growth alongside improving gross and net margins indicates durable demand for the company’s products and improving pricing or cost structure. Over 2–6 months this supports reinvestment, higher operating leverage, and the capacity to fund new launches or specialty product development.
Negative Factors
Generic Market Pressure
Aurobindo’s core generics business faces structural pricing and volume volatility from tender processes, aggressive competitor launches and buyer concentration. These dynamics can erode margins and revenue predictability over the medium term, requiring constant cost control and product diversification.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & Margins
Sustained top-line growth alongside improving gross and net margins indicates durable demand for the company’s products and improving pricing or cost structure. Over 2–6 months this supports reinvestment, higher operating leverage, and the capacity to fund new launches or specialty product development.
Read all positive factors
Aurobindo Pharma Ltd (AUROPHARMA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹784.08B
Dividend Yield0.33%
Average Volume (3M)40.80K
Price to Earnings (P/E)18.9
Beta (1Y)0.78
Revenue Growth7.33%
EPS Growth-3.79%
CountryIN
Employees26,015
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)15.67
Shares Outstanding580,801,640
10 Day Avg. Volume31,329
30 Day Avg. Volume40,801
Financial Highlights & Ratios
PEG Ratio1.81
Price to Book (P/B)2.02
Price to Sales (P/S)2.08
P/FCF Ratio33.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,385.00Price Target Upside14.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)75.18
Revenue Forecast (FY)₹379.01B
Aurobindo Pharma Ltd Business Overview & Revenue Model
Company Description
Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. The company primarily offers oral solids, injectables, and over-the-...
How the Company Makes Money
Aurobindo Pharma primarily makes money by manufacturing and selling (1) finished dosage form pharmaceuticals (generic formulations) and (2) active pharmaceutical ingredients (APIs). Its largest revenue engine is typically the sale of generic formu...
Aurobindo Pharma Ltd Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 325.14B | 317.24B | 290.02B | 248.55B | 234.55B | 247.75B |
| Gross Profit | 170.29B | 182.40B | 160.16B | 132.14B | 130.06B | 145.85B |
| EBITDA | 67.02B | 64.36B | 57.64B | 36.34B | 43.11B | 53.95B |
| Net Income | 34.22B | 34.86B | 31.73B | 19.27B | 26.48B | 53.35B |
Balance Sheet | ||||||
| Total Assets | 525.46B | 497.85B | 450.72B | 398.90B | 339.22B | 338.54B |
| Cash, Cash Equivalents and Short-Term Investments | 88.92B | 82.36B | 63.25B | 62.24B | 45.58B | 56.21B |
| Total Debt | 77.94B | 82.63B | 66.48B | 52.86B | 32.79B | 53.39B |
| Total Liabilities | 175.12B | 171.38B | 152.21B | 130.38B | 93.48B | 119.25B |
| Stockholders Equity | 350.41B | 326.53B | 298.43B | 268.40B | 245.76B | 219.30B |
Cash Flow | ||||||
| Free Cash Flow | 15.22B | 19.57B | -11.27B | -3.34B | 23.12B | 14.55B |
| Operating Cash Flow | 28.85B | 39.25B | 24.35B | 23.87B | 50.16B | 33.29B |
| Investing Cash Flow | -22.23B | -18.76B | -42.56B | -39.78B | -32.12B | 5.99B |
| Financing Cash Flow | -9.43B | 1.20B | 8.00B | 18.14B | -29.69B | -13.65B |
Aurobindo Pharma Ltd Technical Analysis
Positive
1207.35
Price Trends
1235.52
Positive
1216.84
Positive
1159.39
Positive
Market Momentum
30.85
Negative
65.93
Neutral
73.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AUROPHARMA, the sentiment is Positive. The current price of 1207.35 is below the 20-day moving average (MA) of 1307.32, below the 50-day MA of 1235.52, and above the 200-day MA of 1159.39, indicating a bullish trend. The MACD of 30.85 indicates Negative momentum. The RSI at 65.93 is Neutral, neither overbought nor oversold. The STOCH value of 73.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:AUROPHARMA.
Aurobindo Pharma Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹784.08B | 18.87 | ― | 0.33% | 7.33% | -3.79% | |
72 Outperform | ₹650.45B | 25.97 | ― | 0.80% | 9.32% | 11.25% | |
72 Outperform | ₹1.07T | 20.49 | ― | 0.57% | 15.49% | 64.37% | |
72 Outperform | ₹921.16B | 22.07 | ― | 1.19% | 14.01% | 14.62% | |
66 Neutral | ₹592.71B | 59.42 | ― | 0.15% | 25.83% | 421.20% | |
53 Neutral | ₹610.37B | 35.61 | ― | 0.24% | 30.27% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,350.00
219.10
19.37%
IN:ALKEM
Alkem Laboratories Ltd.
5,440.10
606.74
12.55%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,162.90
790.87
57.64%
IN:LAURUSLABS
Laurus Labs Ltd.
1,097.90
473.87
75.94%
IN:LUPIN
Lupin Limited
2,332.70
333.07
16.66%
IN:ZYDUSLIFE
Zydus Lifesciences Limited
915.45
41.27
4.72%
Aurobindo Pharma Ltd Corporate Events
Aurobindo Pharma Board Clears ₹800-Crore Share Buyback via Tender Offer
Apr 6, 2026
Aurobindo Pharma’s board has approved a share buyback of up to 5,423,728 fully paid equity shares, representing about 0.93% of its paid-up equity capital, at a price of ₹1,475 per share for a total consideration of up to ₹800 cro...
Aurobindo Pharma Transfers Domestic Branded Generics Business to Subsidiary
Apr 6, 2026
Aurobindo Pharma’s board has approved the transfer of its domestic branded generic pharmaceutical formulations business to its wholly owned subsidiary, Auropharm Limited, via a Business Transfer Agreement. The move aligns with the company...
Aurobindo Pharma Clears ₹800-Crore Share Buyback at ₹1,475 a Share
Apr 6, 2026
Aurobindo Pharma’s board has approved a share buyback of up to 5,423,728 fully paid equity shares, representing up to 0.93% of its paid-up equity capital, at a price of ₹1,475 per share for a total consideration of up to ₹800 cro...
Aurobindo Pharma Schedules Analyst and Investor Plant Visit to Vizag and Kakinada
Mar 11, 2026
Aurobindo Pharma Limited has notified stock exchanges that its officials will participate in an analyst and investor group plant visit on March 16, 2026. The in-person visit, scheduled from 9:00 a.m. to 5:00 p.m. IST, will take place at the compan...
Aurobindo Pharma Schedules Analyst and Investor Plant Visit to Vizag and Kakinada
Mar 11, 2026
Aurobindo Pharma has notified stock exchanges that its officials will participate in an in-person analyst and investor group plant visit to its facilities in Vizag and Kakinada on March 17, 2026, scheduled from 9:00 a.m. to 5:00 p.m. Indian Standa...
Aurobindo Pharma to Join Goldman Sachs India Pharma Corporate Days Investor Meet
Mar 2, 2026
Aurobindo Pharma Limited has notified stock exchanges that its officials will participate in Goldman Sachs India Pharma Corporate Days, an investor conference scheduled as a virtual meeting on March 6, 2026. The company emphasized that no unpublis...
Aurobindo Pharma Says Share Volume Surge Is Market-Driven Amid MIP Notification on Key Antibiotics
Feb 2, 2026
Aurobindo Pharma has clarified to the National Stock Exchange of India and BSE that the recent significant increase in trading volumes of its shares is, in its view, purely market driven and not prompted by any undisclosed price-sensitive informat...
Aurobindo Pharma Schedules Q3 FY26 Analyst and Investor Earnings Call
Feb 2, 2026
Aurobindo Pharma has notified the stock exchanges that it will host an analyst and investor earnings call on 10 February 2026 at 8:30 a.m. IST to discuss its unaudited financial results for the third quarter and nine-month period ended 31 December...
Aurobindo Pharma Says Share Volume Surge Is Market-Driven Amid Antibiotic MIP Move
Jan 31, 2026
Aurobindo Pharma has clarified that the recent significant increase in trading volumes of its shares is, in its view, purely market driven and not the result of any undisclosed, company-specific developments. The company attributed heightened mark...
Aurobindo Pharma Says Surge in Share Volume Is Market Driven, Not Due to Undisclosed Events
Jan 31, 2026
Aurobindo Pharma has clarified to the National Stock Exchange of India and BSE that the recent significant increase in trading volumes of its shares is market driven and not the result of any undisclosed, company-specific information. The company ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.